Brain Biotech

Historical price data

BRAIN Biotech AG is a technology and service provider focused on industrial biotechnology, operating as a publicly traded company on the Frankfurt Stock Exchange. Its mission is to create a #BiobasedFuture by providing customized research and development solutions for clients facing scientific challenges in enzyme, protein, and microorganism development. The company's value proposition centers on saving clients time and resources, driving innovation, offering flexibility, and reducing project risk through its advanced technology portfolio and multi-disciplinary expertise. Its strategic direction involves scaling its proprietary platforms, such as its methanol-free Komagataella phaffii protein production system, to serve the growing demand for sustainable industrial bioprocesses.

A modular technology portfolio for industrial biotechnology, comprising proprietary platforms for methanol-free recombinant protein production in Komagataella phaffii, CRISPR-BMC genome editing for microbial strains, and integrated services for enzyme engineering and bioprocess scale-up.

238 drugs in pipeline, 21 in Phase 3

Total raised: $17.5M

Competes with large life science tool providers (e.g., Merck, Thermo Fisher), specialist CDMOs (e.g., Lonza), and industrial biotech leaders (e.g., Novozymes). BRAIN Biotech differentiates through its specialized industrial focus, integrated service model from discovery to scale-up, and proprietary technologies like its methanol-free protein expression system.